Predictive value of rectal aberrant crypt foci for intraepithelial neoplasia in ulcerative colitis-a cross-sectional study

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 10, 2014, Pages 1219-1229

  Freire, Paulo ^a   Figueiredo, Pedro ^a,b   Cardoso, Ricardo ^a   Manuel Donato, Maria ^b   Ferreira, Manuela ^a   Mendes, Sofia ^a   Silva, Mário Rui ^a   Cipriano, Maria Augusta ^a   Ferreira, Ana Margarida ^a   Vasconcelos, Helena ^c   Portela, Francisco ^a   Sofia, Carlos ^a,b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c Hospital Santo André de Leiria   (Portugal)

Author keywords

Aberrant crypt foci; Chromoendoscopy; Intraepithelial neoplasia; Surveillance; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID;

ABERRANT CRYPT FOCUS; ADULT; ARTICLE; BODY MASS; CALIBRATION; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CHROMOENDOSCOPY; CLINICAL ASSESSMENT; CLINICAL FEATURE; COLONOSCOPY; COLORECTAL CANCER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; HUMAN; INTRAEPITHELIAL NEOPLASIA; MAJOR CLINICAL STUDY; MIDDLE AGED; PREDICTIVE VALUE; PREVALENCE; RECEIVER OPERATING CHARACTERISTIC; RECTAL ABERRANT CRYPT FOCI; RECTUM; RECTUM CANCER; RISK FACTOR; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; ABERRANT CRYPT FOCI; AGE; AGED; AREA UNDER THE CURVE; CARCINOMA IN SITU; COLORECTAL NEOPLASMS; COMPLICATION; FEMALE; GENETICS; MALE; MICROSCOPY; PATHOLOGY; PROSPECTIVE STUDY;

ABERRANT CRYPT FOCI; ADULT; AGE FACTORS; AGED; AREA UNDER CURVE; BODY MASS INDEX; CARCINOMA IN SITU; COLITIS, ULCERATIVE; COLONOSCOPY; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MICROSCOPY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; RECTUM; RISK FACTORS; ROC CURVE;

EID: 84907242391     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.951390     Document Type: Article

References (80)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-Analysis. Gut 2001;48: 526-35.
2. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: A meta-Analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10:639-45.
3. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-85.
4. Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P,MoserG, et al. SecondEuropean evidence-based consensusonthe diagnosis andmanagementof ulcerativecolitis part 3: Special situations. J Crohns Colitis 2013;7:1-33.
5. Farraye FA, Odze RD, Eaden J, Itzkowitz SH, McCabe RP, Dassopoulos T, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010;138: 738-45.
6. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-89.
7. Guagnozzi D, Lucendo AJ. Colorectal cancer surveillance in patients with inflammatory bowel disease: What is new? World J Gastrointest Endosc 2012;4:108-16.
8. Mattar MC, Lough D, Pishvaian MJ, Charabaty A. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res 2011;4:53-61.
9. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: What is the real magnitude of the risk? World J Gastroenterol 2012;18:3839-48.
10. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: A meta-Analysis. Gastrointest Endosc 2002;56:48-54.
11. Efthymiou M, Taylor AC, Kamm MA. Cancer surveillance strategies in ulcerative colitis: The need for modernization. Inflamm Bowel Dis 2011;17:1800-13.
12. Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, et al. Risk factors for ulcerative colitis-Associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: Results of a population-based study. Inflamm Bowel Dis 2006;12:205-11.
13. Figueiredo P, Donato M, Urbano M, Goulão H, Gouveia H, Sofia C, et al. Aberrant crypt foci: Endoscopic assessment and cell kinetics characterization. Int J Colorectal Dis 2009;24: 441-50.
14. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339: 1277-84.
15. Adler DG, Gostout CJ, Sorbi D, Burgart LJ, Wang L, Harmsen WS. Endoscopic identification and quantification of aberrant crypt foci in the human colon. Gastrointest Endosc 2002;56:657-62.
16. Hurlstone DP, Karajeh M, Sanders DS, Drew SK, Cross SS. Rectal aberrant crypt foci identified using high-magnificationchromoscopic colonoscopy: Biomarkers for flat and depressed neoplasia. Am J Gastroenterol 2005;100:1283-9.
17. Seike K, Koda K, Oda K, Kosugi C, Shimizu K, Nishimura M, et al. Assessment of rectal aberrant crypt foci by standard chromoscopy and its predictive value for colonic advanced neoplasms. Am J Gastroenterol 2006;101:1362-9.
18. Lopez-Ceron M, Pellise M. Biology and diagnosis of aberrant crypt foci. Colorectal Dis 2012;14:e157-64.
19. Alrawi SJ, Schiff M, Carroll RE, Dayton M, Gibbs JF, Kulavlat M, et al. Aberrant crypt foci. Anticancer Res 2006;26:107-19.
20. Siu IM, Robinson DR, Schwartz S, Kung HJ, Pretlow TG, Petersen RB, et al. The identification of monoclonality in human aberrant crypt foci. Cancer Res 1999;59:63-6.
21. Pretlow TP, Pretlow TG. Putative preneoplastic changes identified by enzyme histochemical and immunohistochemical techniques. J Histochem Cytochem 1998;46:577-83.
22. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
23. Yamashita N, Minamoto T, Ochiai A, Onda M, Esumi H. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 1995;108:434-40.
24. Beach R, Chan AO, Wu TT, White JA, Morris JS, Lunagomez S, et al. BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol 2005;166:1069-75.
25. Shivapurkar N, Huang L, Ruggeri B, Swalsky PA, Bakker A, Finkelstein S, et al. K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients. Cancer Lett 1997;115:39-46.
26. Sakurazawa N, Tanaka N, Onda M, Esumi H. Instability of X chromosome methylation in aberrant crypt foci of the human colon. Cancer Res 2000;60:3165-9.
27. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004;126:1634-48.
28. Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: Potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 2009;6:297-305.
29. Kukitsu T, Takayama T, Miyanishi K, Nobuoka A, Katsuki S, Sato Y, et al. Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis. Clin Cancer Res 2008;14:48-54.
30. Moxon D, Raza M, Kenney R, Ewing R, Arozullah A, Mason JB, et al. Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population. Clin Gastroenterol Hepatol 2005;3:271-8.
31. Kim J, Ng J, Arozulllah A, Ewing R, Llor X, Carroll RE, et al. Aberrant crypt focus size predicts distal polyp histopathology. Cancer Epidemiol Biomarkers Prev 2008;17:1155-62.
32. Anderson JC, Pleau DC, Rajan TV, Protiva P, Swede H, Brenner B, et al. Increased frequency of serrated aberrant crypt foci among smokers. Am J Gastroenterol 2010;105: 1648-54.
33. Stevens RG, Swede H, Heinen CD, Jablonski M, Grupka M, Ross B, et al. Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer. Cancer Lett 2007;248:262-8.
34. Anderson JC, Swede H, Rustagi T, Protiva P, Pleau D, Brenner BM, et al. Aberrant crypt foci as predictors of colorectal neoplasia on repeat colonoscopy. Cancer Causes Control 2012;23:355-61.
35. Takahashi H, Takayama T, Yoneda K, Endo H, Iida H, Sugiyama M, et al. Association of visceral fat accumulation and plasma adiponectin with rectal dysplastic aberrant crypt foci in a clinical population. Cancer Sci 2009;100:29-32.
36. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;170:2-6.discussion 16-9.
37. Sands BE. From symptom to diagnosis: Clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004;126:1518-32.
38. Podolsky DK. Inflammatory bowel disease (2).NEngl JMed 1991;325:1008-16.
39. Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: Definitions and diagnosis. J Crohns Colitis 2012;6: 965-90.
40. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management. J Crohns Colitis 2012;6:991-1030.
41. Greenstein AJ, Sachar DB, Smith H, Pucillo A, Papatestas AE, Kreel I, et al. Cancer in universal and leftsided ulcerative colitis: Factors determining risk. Gastroenterology 1979;77:290-4.
42. Centers for Disease Control and Prevention. State-specific secondhand smoke exposure and current cigarette smoking among adults-United States, 2008. MMWR 2009;58: 1232-5.
43. Kiesslich R, Neurath MF. Chromoendoscopy: An evolving standard in surveillance for ulcerative colitis. Inflamm Bowel Dis 2004;10:695-6.
44. Paris Workshop Participants. The Paris endoscopic classification of superficial neoplastic lesions: Esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003;58:S3-43; Review.
45. Kiesslich R, Goetz M, Lammersdorf K, Schneider C, Burg J, Stolte M, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 2007;132:874-82.
46. Mutch MG, Schoen RE, Fleshman JW, Rall CJ, Dry S, Seligson D, et al. A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol 2009;7:568-74.
47. Roncucci L, Medline A, Bruce WR. Classification of aberrant crypt foci and microadenomas in human colon. Cancer Epidemiol Biomarkers Prev 1991;1:57-60.
48. Roncucci L, Stamp D, Medline A, Cullen JB, Bruce WR. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991;22: 287-94.
49. Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, et al. Aberrant crypts: Putative preneoplastic foci in human colonic mucosa. Cancer Res 1991;51:1564-7.
50. Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA. Aberrant crypts in human colonic mucosa: Putative preneoplastic lesions. J Cell Biochem Suppl 1992;16G:55-62.
51. Schoen RE, Mutch M, Rall C, Dry SM, Seligson D, Umar A, et al. The natural history of aberrant crypt foci. Gastrointest Endosc 2008;67:1097-102.
52. Gupta AK, Pinsky P, Rall C, Mutch M, Dry S, Seligson D, et al. Reliability and accuracy of the endoscopic appearance in the identification of aberrant crypt foci. Gastrointest Endosc 2009;70:322-30.
53. Pinsky PF, Fleshman J, Mutch M, Rall C, Charabaty A, Seligson D, et al. One year recurrence of aberrant crypt foci. Cancer Prev Res (Phila) 2010;3:839-43.
54. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251-5.
55. Lemeshow S, Hosmer Jr. D.W. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982;115:92-106.
56. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
57. Youden WJ. Index for rating diagnosis tests. Cancer 1950;3: 32-5.
58. Mooiweer E, van der Meulen AE, van Bodegraven AA, Jansen JM, Mahmmod N, Nijsten J, et al. Neoplasia yield and colonoscopic workload of surveillance regimes for colorectal cancer in colitis patients: A retrospective study comparing the performance of the updated AGA and BSG guidelines. Inflamm Bowel Dis 2013;19:2603-10.
59. Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: An analysis of performance. Gastrointest Endosc 2000;51:123-8.
60. Gearry RB, Wakeman CJ, Barclay ML, Chapman BA, Collett JA, Burt MJ, et al. Surveillance for dysplasia in patients with inflammatory bowel disease: A national survey of colonoscopic practice in New Zealand. Dis Colon Rectum 2004;47:314-22.
61. Kaltz B, Bokemeyer B, Hoffmann J, Porschen R, Rogler G, Schmiegel W. Surveillance colonoscopy in ulcerative colitis patients in Germany. Z Gastroenterol 2007;45:325-31.
62. Ullman TA, Croog V, Harpaz N, Itzkowitz S. Biopsy specimen numbers in the routine practice of surveillance colonoscopy in ulcerative colitis (UC). Gastroentrology 2004; 126:A471.
63. Rodriguez SA, Eisen GM. Surveillance and management of dysplasia in ulcerative colitis by U.S. gastroenterologists: In truth, a good performance. Gastrointest Endosc 2007;66: 1070.
64. van Rijn AF, Fockens P, Siersema PD, Oldenburg B. Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn's colitis patients in the Netherlands. World J Gastroenterol 2009;15:226-30.
65. Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, et al. Chromoendoscopy-Targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: A prospective endoscopic trial. Am J Gastroenterol 2008; 103:2342-9.
66. Orlando FA, Tan D, Baltodano JD, Khoury T, Gibbs JF, Hassid VJ, et al. Aberrant crypt foci as precursors in colorectal cancer progression. J Surg Oncol 2008;98:207-13.
67. Shpitz B, Bomstein Y, Mekori Y, Cohen R, Kaufman Z, Neufeld D, et al. Aberrant crypt foci in human colons: Distribution and histomorphologic characteristics. Hum Pathol 1998;29:469-75.
68. Yokota T, Sugano K, Kondo H, Saito D, Sugihara K, Fukayama N, et al. Detection of aberrant crypt foci by magnifying colonoscopy. Gastrointest Endosc 1997;46:61-5.
69. Bouzourene H, Chaubert P, Seelentag W, Bosman FT, Saraga E. Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease. Hum Pathol 1999;30:66-71.
70. Hurlstone DP, Cross SS. Role of aberrant crypt foci detected using high-magnification-chromoscopic colonoscopy in human colorectal carcinogenesis. J Gastroenterol Hepatol 2005;20:173-81.
71. Mascolo M, Staibano S, Ilardi G, Siano M, Vecchione ML, Esposito D, et al. Probe-based confocal laser endomicroscopy evaluation of colon preneoplastic lesions, with particular attention to the aberrant crypt foci, and comparative assessment with histological features obtainedbyconventionalendoscopy. Gastroenterol Res Pract 2012;2012:645173.
72. Rudolph RE, Dominitz JA, Lampe JW, Levy L, Qu P, Li SS, et al. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev 2005;14:605-8.
73. Sakai E, Takahashi H, Kato S, Uchiyama T, Hosono K, Endo H, et al. Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm. Cancer Epidemiol Biomarkers Prev 2011;20:1918-24.
74. Shpitz B, Klein E, Buklan G, Neufeld D, Nissan A, Freund HR, et al. Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut 2003;52: 1598-601.
75. Johnson IT. New approaches to the role of diet in the prevention of cancers of the alimentary tract. Mutat Res 2004;551:9-28.
76. Gupta AK, Pretlow TP, Schoen RE. Aberrant crypt foci: What we know and what we need to know. Clin Gastroenterol Hepatol 2007;5:526-33.
77. Gupta AK, Schoen RE. Aberrant crypt foci: Are they intermediate endpoints of colon carcinogenesis in humans? Curr Opin Gastroenterol 2009;25:59-65.
78. Siu IM, Pretlow TG, Amini SB, Pretlow TP. Identification of dysplasia in human colonic aberrant crypt foci. Am J Pathol 1997;150:1805-13.
79. Suehiro Y, Hinoda Y. Genetic and epigenetic changes in aberrant crypt foci and serrated polyps. Cancer Sci 2008;99: 1071-6.
80. Otori K, Sugiyama K, Hasebe T, Fukushima S, Esumi H. Emergence of adenomatous aberrant crypt foci (ACF) from hyperplastic ACF with concomitant increase in cell proliferation. Cancer Res 1995;55:4743-6.